Current and future perspectives of PD‐1/PDL‐1 blockade in cancer immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has
yielded great success in recent years. Among immunotherapeutic agents, immune …
yielded great success in recent years. Among immunotherapeutic agents, immune …
Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology
The deep and durable antitumor effects of antibody-based immunotherapies such as
immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the …
immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the …
Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 …
Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with
advanced disease not eligible for potentially curative therapies; therefore, new treatment …
advanced disease not eligible for potentially curative therapies; therefore, new treatment …
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O'Reilly, DY Oh, N Dhani, DJ Renouf… - JAMA …, 2019 - jamanetwork.com
Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …
Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology
JA Thompson, BJ Schneider, J Brahmer… - Journal of the National …, 2019 - jnccn.org
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …
provide guidance on the management of immune-related adverse events resulting from …
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer
M Masetti, R Carriero, F Portale, G Marelli… - Journal of Experimental …, 2021 - rupress.org
Tumor-associated macrophages (TAMs) are correlated with the progression of prostatic
adenocarcinoma (PCa). The mechanistic basis of this correlation and therapeutic strategies …
adenocarcinoma (PCa). The mechanistic basis of this correlation and therapeutic strategies …
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma
H Murai, T Kodama, K Maesaka, S Tange… - Hepatology, 2023 - journals.lww.com
Multiomics identifies the link between intratumor steatosis... : Hepatology Multiomics
identifies the link between intratumor steatosis and the exhausted tumor immune …
identifies the link between intratumor steatosis and the exhausted tumor immune …
Decorating bacteria with triple immune nanoactivators generates tumor‐resident living immunotherapeutics
An approach of decorating bacteria with triple immune nanoactivators is reported to develop
tumor‐resident living immunotherapeutics. Under cytocompatible conditions, tumor‐specific …
tumor‐resident living immunotherapeutics. Under cytocompatible conditions, tumor‐specific …
CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion
M Wang, J Jia, Y Cui, Y Peng, Y Jiang - Cell death & disease, 2021 - nature.com
Extracellular vesicles are involved in the occurrence, progression and metastasis of
glioblastoma (GBM). GBM can secrete a variety of tumour-derived extracellular vesicles …
glioblastoma (GBM). GBM can secrete a variety of tumour-derived extracellular vesicles …
Near-infrared photoimmunotherapy of cancer: A new approach that kills cancer cells and enhances anti-cancer host immunity
H Kobayashi, A Furusawa, A Rosenberg… - International …, 2021 - academic.oup.com
Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed hybrid cancer therapy
that directly kills cancer cells as well as producing a therapeutic host immune response …
that directly kills cancer cells as well as producing a therapeutic host immune response …